# Semaglutide

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/semaglutide
Canonical HTML page: https://gethealthbrief.com/entity/semaglutide

## Recent coverage (2 stories)

### Wegovy Pill Approved With 87% of Patients Losing ≥5% Body Weight
2026-06-15 08:00:50 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

The MHRA approval of Novo Nordisk's oral semaglutide for obesity triggers a private prescribing boom, with pharmacies reporting 100,000 on waiting lists. The pill shows 87% of adherent patients in trials lost at least 5% body weight, with one in three losing 20%+. NHS discussions are under way, but no coverage timeline is set, leaving patients to navigate private costs.
Full story: https://gethealthbrief.com/story/wegovy-pill-mhra-approval-87-percent-weight-loss

### Zydus Disrupts Indian GLP-1 Market with Reusable Semaglutide Pen
2026-03-21 16:55:04 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Zydus Lifesciences has launched a Semaglutide injection in India featuring a first-of-its-kind reusable multi-dose pen device. This move aims to improve accessibility and affordability for patients managing Type 2 diabetes and obesity in a high-growth market.
Full story: https://gethealthbrief.com/story/zydus-launches-reusable-semaglutide-pen-india

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.